Minh Doan
Engineering antigens for in situ erythrocyte binding induces T-cell deletion
Stephen Konos, Iraklis C. Kourtisa, Karen Y. Danea, and Jeffrey A. Hubbell
Proceedings of the National Academy of Sciences of the United States of America
Stephen Konos’ is the co-founder of Ankonion, which is a research lab focused on
manipulating binding tolerances of immune cells to treat autoimmune diseases. Specifically, his
thesis focused on developing red blood cell tolerance technology and observing the effects on
the immune system. This study seeks to address how antigens can be used to suppress
immune responses and induce T cell deletion in order to treat autoimmune diseases.
One of the methods utilized in this study was the utilization of OVA antigens as a
reference protein to induce and measure immune responses within the cell. In immunological
studies, OVA is used to study antigen specific immune responses, because they are nontoxic
and have work rapidly, making it the model antigen. In the study, different OVA variants were
created with high binding affinities for erythrocytes to measure their binding kinetics and red
blood cell clearance.
You've reached the end of your free preview.
Want to read all 3 pages?
- Spring '14
- GaryL.Bowlin
